Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 7/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611607 | 0.94 | CCR3 (0.59) | CCR3ACHEBCHECXCR4LTA4H | |
| SCHEMBL5228406 | 0.90 | CCR3 (0.63) | CCR3ACHEBCHECXCR4LTA4H | |
| SCHEMBL6823142 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHECXCR4LTA4H | |
| SCHEMBL8340597 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHECXCR4LTA4H | |
| SCHEMBL15140944 | 0.87 | CCR3 (0.73) | CCR3ACHEBCHECXCR4ALDH1A1 | |
| SCHEMBL349053 | 0.86 | CCR3 (0.71) | CCR3ACHEBCHECXCR4LTA4H | |
| SCHEMBL3107807 | 0.86 | CCR3 (0.71) | CCR3ACHEBCHECXCR4ALDH1A1 | |
| SCHEMBL24404498 | 0.84 | CCR3 (0.69) | CCR3ACHEBCHE | |
| Hydrochloric Acid SCHEMBL10385903 | 0.84 | CCR3 (0.69) | CCR3ACHEBCHECXCR4ALDH1A1 | |
| SCHEMBL4499901 | 0.84 | CCR3 (0.69) | CCR3ACHEBCHECXCR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486250-B2 | Muscarinic receptor 4 antagonists and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4069367-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| CN-115536696-B | ENPP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115536696-A | ENPP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4069367-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-1992002502-A1 | N-HYDROCARBYL-4-SUBSTITUTED PIPERIDINES, THEIR PREPARATION AND USE AS CALCIUM BLOCKING AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-02-20 | — | — | WO | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
| EP-0398425-A1 | Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| EP-0320032-A1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-14 | — | — | EP | disclosed |
| CN-1033274-A | The preparation method of new Pyridazinyl amine derivative | JANSSEN PHARMACEUTICA NV (BE) | 1989-06-07 | — | — | CN | disclosed |
| EP-0135318-B1 | QUINAZOLINE CARDIAC STIMULANTS | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
| US-4542132-A | HYDROXY SUBSTITUTED | PFIZER INC. (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0135318-A1 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1985-03-27 | — | — | EP | disclosed |
| EP-0017411-B1 | PHTHALAZINE CARDIAC STIMULANTS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1982-03-31 | — | — | EP | disclosed |
| EP-0017411-A1 | Phthalazine cardiac stimulants, processes for preparing them, and pharmaceutical compositions containing them | Pfizer Limited (GB) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM3 | CCR3 806/4885ACHE 114/4885BCHE 415/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CCR3 1465/4885ACHE 4288/4885BCHE 4767/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CCR3 1465/4885ACHE 4288/4885BCHE 4767/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CCR3 1465/4885ACHE 4288/4885BCHE 4767/4885 |
| US-12486250-B2 | Muscarinic receptor 4 antagonists and methods of use | CHRM4, CHRM2, CHRM3 | CCR3 806/4885ACHE 114/4885BCHE 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.